ZYDUSLIFE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.3
| Stock Code | ZYDUSLIFE | Market Cap | 1,04,568 Cr. | Current Price | 1,039 ₹ | High / Low | 1,094 ₹ |
| Stock P/E | 28.3 | Book Value | 235 ₹ | Dividend Yield | 0.10 % | ROCE | 16.6 % |
| ROE | 16.5 % | Face Value | 1.00 ₹ | DMA 50 | 942 ₹ | DMA 200 | 935 ₹ |
| Chg in FII Hold | -0.11 % | Chg in DII Hold | 0.12 % | PAT Qtr | 1,806 Cr. | PAT Prev Qtr | 343 Cr. |
| RSI | 69.4 | MACD | 31.5 | Volume | 13,30,092 | Avg Vol 1Wk | 50,57,077 |
| Low price | 836 ₹ | High price | 1,094 ₹ | PEG Ratio | 0.90 | Debt to equity | 0.31 |
| 52w Index | 78.7 % | Qtr Profit Var | -35.8 % | EPS | 35.4 ₹ | Industry PE | 30.5 |
📊 Core Financials:
ZYDUSLIFE has delivered strong financials with quarterly PAT at 1,806 Cr., up significantly from 343 Cr. despite a reported profit variation of -35.8% due to prior base effects. ROCE at 16.6% and ROE at 16.5% are healthy, reflecting efficient capital utilization. Debt-to-equity is moderate at 0.31, indicating manageable leverage. EPS stands at 35.4 ₹, supported by consistent profitability and strong cash flows.
💹 Valuation Indicators:
The stock trades at a P/E of 28.3, slightly below the industry average of 30.5, suggesting fair valuation. P/B ratio is ~4.42 (Price 1,039 ₹ / Book Value 235 ₹), which is elevated but justified by earnings strength. PEG ratio of 0.90 indicates growth is reasonably priced. Intrinsic value appears close to current levels, offering moderate margin of safety.
🏢 Business Model & Competitive Advantage:
ZYDUSLIFE operates in pharmaceuticals with a diversified product portfolio across generics, specialty drugs, and vaccines. Its competitive advantage lies in scale, R&D capabilities, and strong domestic and global presence. Healthy ROCE and ROE highlight efficient operations, though institutional confidence has weakened slightly with reduced FII holdings.
🎯 Entry Zone & Long-Term Guidance:
Current price (1,039 ₹) is above both 50 DMA (942 ₹) and 200 DMA (935 ₹), showing bullish momentum. RSI at 69.4 indicates near overbought conditions, while MACD (31.5) confirms strong positive momentum. A good entry zone would be 1,000–1,030 ₹ if undervaluation emerges. Long-term holding is favorable given strong fundamentals, sector resilience, and growth potential.
Positive
- 📈 Quarterly PAT surged to 1,806 Cr.
- 💰 Strong ROCE (16.6%) and ROE (16.5%).
- 📊 Attractive P/E (28.3) vs industry average (30.5).
- 🌍 DII holdings increased (+0.12%).
Limitation
- ⚠️ Elevated P/B ratio (~4.42).
- 📉 RSI near overbought (69.4), risk of correction.
- 📉 Dividend yield modest at 0.10%.
- 📉 FII holdings reduced (-0.11%).
Company Negative News
📰 No major negative news reported recently, but slight reduction in FII holdings and high RSI raise caution for short-term investors.
Company Positive News
📰 Quarterly earnings surged, highlighting strong operational performance. Technical indicators show bullish momentum, and fundamentals remain robust.
Industry
🏭 Industry P/E stands at 30.5, slightly higher than ZYDUSLIFE’s valuation. The pharmaceutical sector remains resilient, driven by global healthcare demand, innovation, and government support.
Conclusion
✅ ZYDUSLIFE is financially strong with efficient capital utilization, fair valuation, and sector resilience. Best suited for long-term investors who can accumulate near 1,000–1,030 ₹. Short-term traders should remain cautious due to near overbought technical signals despite strong fundamentals.
Would you like me to extend this into a pharma sector outlook to evaluate how industry trends could influence ZYDUSLIFE’s growth trajectory?